HRP20190920T1 - Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba - Google Patents
Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba Download PDFInfo
- Publication number
- HRP20190920T1 HRP20190920T1 HRP20190920TT HRP20190920T HRP20190920T1 HR P20190920 T1 HRP20190920 T1 HR P20190920T1 HR P20190920T T HRP20190920T T HR P20190920TT HR P20190920 T HRP20190920 T HR P20190920T HR P20190920 T1 HRP20190920 T1 HR P20190920T1
- Authority
- HR
- Croatia
- Prior art keywords
- benralizumab
- use according
- patient
- optionally
- administration
- Prior art date
Links
- 229950000321 benralizumab Drugs 0.000 title claims 20
- 208000006673 asthma Diseases 0.000 title claims 6
- 230000005713 exacerbation Effects 0.000 claims 5
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 2
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 229940125389 long-acting beta agonist Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Claims (12)
1. Učinkovita količina benralizumaba za upotrebu u postupku liječenja astme povećanjem volumena prisilnog izdisaja u jednoj sekundi (FEV1) kod pacijenta s astmom, pri čemu primjena povećava pacijentov FEV1, naznačen time što se benralizumab primjenjuje u dozi od 30 mg jednom svaka četiri tjedna tijekom dvanaest tjedana i zatim jednom svakih osam tjedana.
2. Benralizumab za uporabu prema zahtjevu 1, naznačen time što je astma eozinofilna astma.
3. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time što pacijent ima broj eozinofila u krvi od najmanje 300 stanica/µl.
4. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što pacijent ima prisilan volumen izdisaja u jednoj sekundi (FEV1) od najmanje 75% predviđene vrijednosti prije primjene.
5. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što pacijent ima rezultat kontrolnog upitnika za astmu od najmanje 1.5 prije primjene.
6. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što povećava pacijentov FEV1 nakon primjene benralizumaba.
7. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što se FEV1 povećava za najmanje 0.1 L, po izboru za najmanje 0.13 L, po izboru za najmanje 0.2 L, po izboru za najmanje 0.25 L, po izboru za najmanje 0.5 L.
8. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što pacijent koristi visoku dozu inhalacijskih kortikosteroida (ICS).
9. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što pacijent koristi dugodjelujuće β2 agoniste (LABA).
10. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-9, naznačen time što pacijent ima povijest egzacerbacija, po izboru pri čemu povijest egzacerbacija obuhvaća barem dvije egzacerbacije godišnje prije primjene benralizumaba, po izboru pri čemu povijest egzacerbacija obuhvaća ne više od šest egzacerbacija godišnje prije primjene benralizumaba.
11. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-10, naznačen time što se benralizumab primjenjuje parenteralno, po izboru pri čemu se benralizumab primjenjuje potkožno.
12. Benralizumab za uporabu prema bilo kojem od patentnih zahtjeva 1-11, naznačen time što se benralizumab primjenjuje uz terapiju kortikosteroidima.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864948P | 2013-08-12 | 2013-08-12 | |
| EP14836725.3A EP3033104B1 (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
| PCT/US2014/050119 WO2015023507A2 (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190920T1 true HRP20190920T1 (hr) | 2019-07-12 |
Family
ID=52448838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190920TT HRP20190920T1 (hr) | 2013-08-12 | 2019-05-17 | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba |
| HRP20210406TT HRP20210406T1 (hr) | 2013-08-12 | 2021-03-10 | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210406TT HRP20210406T1 (hr) | 2013-08-12 | 2021-03-10 | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9441046B2 (hr) |
| EP (3) | EP3520811B1 (hr) |
| JP (3) | JP6746496B2 (hr) |
| KR (1) | KR102337599B1 (hr) |
| CN (2) | CN111588849A (hr) |
| AU (2) | AU2014306959B2 (hr) |
| BR (1) | BR112016002317A8 (hr) |
| CA (1) | CA2917603C (hr) |
| CY (2) | CY1122033T1 (hr) |
| DK (2) | DK3033104T3 (hr) |
| ES (2) | ES2733602T3 (hr) |
| HK (2) | HK1222559A1 (hr) |
| HR (2) | HRP20190920T1 (hr) |
| HU (2) | HUE043497T2 (hr) |
| LT (2) | LT3520811T (hr) |
| ME (1) | ME03403B (hr) |
| MX (2) | MX2016001384A (hr) |
| PL (2) | PL3520811T3 (hr) |
| PT (2) | PT3033104T (hr) |
| RS (2) | RS61565B1 (hr) |
| RU (1) | RU2703568C2 (hr) |
| SG (1) | SG11201600483QA (hr) |
| SI (2) | SI3033104T1 (hr) |
| TR (1) | TR201907907T4 (hr) |
| WO (1) | WO2015023507A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3988114A1 (en) * | 2013-08-12 | 2022-04-27 | Astrazeneca AB | Methods for improving asthma symptoms using benralizumab |
| HUE042607T2 (hu) * | 2013-08-12 | 2019-07-29 | Astrazeneca Ab | Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával |
| BR112016008082A2 (pt) * | 2013-10-15 | 2017-10-17 | Medimmune Llc | métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab |
| KR102238065B1 (ko) * | 2013-10-24 | 2021-04-07 | 아스트라제네카 아베 | 안정한 수성 항체 제제 |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE283926T1 (de) | 1995-09-11 | 2004-12-15 | Kyowa Hakko Kogyo Kk | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2402477A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| JPWO2005035583A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | Ｉｌ−５受容体に特異的に結合する抗体組成物 |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| AU2006299429B2 (en) | 2005-10-03 | 2012-02-23 | Xencor, Inc. | Fc variants with optimized Fc receptor binding properties |
| MX2009012341A (es) | 2007-05-14 | 2010-02-17 | Medimmune Llc | Metodos para reducir niveles de eosinofilos. |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| AR084342A1 (es) * | 2010-12-16 | 2013-05-08 | Genentech Inc | Diagnostico y tratamientos relacionados con la inhibicion de th2 |
| CN102544908B (zh) | 2010-12-17 | 2016-01-06 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件及插头连接器 |
| EP2710370A4 (en) | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
| JP2014533246A (ja) * | 2011-11-01 | 2014-12-11 | メディミューン，エルエルシー | 喘息の急性増悪の頻度および重症度を低下させる方法 |
| HUE042607T2 (hu) * | 2013-08-12 | 2019-07-29 | Astrazeneca Ab | Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával |
| EP3988114A1 (en) * | 2013-08-12 | 2022-04-27 | Astrazeneca AB | Methods for improving asthma symptoms using benralizumab |
-
2014
- 2014-08-07 SI SI201431191T patent/SI3033104T1/sl unknown
- 2014-08-07 RU RU2016108809A patent/RU2703568C2/ru active
- 2014-08-07 BR BR112016002317A patent/BR112016002317A8/pt not_active Application Discontinuation
- 2014-08-07 CN CN202010450690.6A patent/CN111588849A/zh active Pending
- 2014-08-07 PL PL19158446T patent/PL3520811T3/pl unknown
- 2014-08-07 JP JP2016534615A patent/JP6746496B2/ja active Active
- 2014-08-07 PL PL14836725T patent/PL3033104T3/pl unknown
- 2014-08-07 ME MEP-2019-137A patent/ME03403B/me unknown
- 2014-08-07 SI SI201431795T patent/SI3520811T1/sl unknown
- 2014-08-07 EP EP19158446.5A patent/EP3520811B1/en active Active
- 2014-08-07 DK DK14836725.3T patent/DK3033104T3/da active
- 2014-08-07 RS RS20210305A patent/RS61565B1/sr unknown
- 2014-08-07 US US14/454,138 patent/US9441046B2/en active Active
- 2014-08-07 WO PCT/US2014/050119 patent/WO2015023507A2/en active Application Filing
- 2014-08-07 PT PT14836725T patent/PT3033104T/pt unknown
- 2014-08-07 DK DK19158446.5T patent/DK3520811T3/da active
- 2014-08-07 LT LTEP19158446.5T patent/LT3520811T/lt unknown
- 2014-08-07 AU AU2014306959A patent/AU2014306959B2/en active Active
- 2014-08-07 EP EP20208316.8A patent/EP3875487A1/en active Pending
- 2014-08-07 CA CA2917603A patent/CA2917603C/en active Active
- 2014-08-07 HU HUE14836725A patent/HUE043497T2/hu unknown
- 2014-08-07 TR TR2019/07907T patent/TR201907907T4/tr unknown
- 2014-08-07 PT PT191584465T patent/PT3520811T/pt unknown
- 2014-08-07 RS RS20190556A patent/RS58711B1/sr unknown
- 2014-08-07 MX MX2016001384A patent/MX2016001384A/es unknown
- 2014-08-07 ES ES14836725T patent/ES2733602T3/es active Active
- 2014-08-07 SG SG11201600483QA patent/SG11201600483QA/en unknown
- 2014-08-07 ES ES19158446T patent/ES2866426T3/es active Active
- 2014-08-07 CN CN201480045047.8A patent/CN105451769A/zh active Pending
- 2014-08-07 KR KR1020167006576A patent/KR102337599B1/ko active IP Right Grant
- 2014-08-07 HU HUE19158446A patent/HUE053627T2/hu unknown
- 2014-08-07 LT LTEP14836725.3T patent/LT3033104T/lt unknown
- 2014-08-07 EP EP14836725.3A patent/EP3033104B1/en active Active
-
2016
- 2016-01-29 MX MX2021003826A patent/MX2021003826A/es unknown
- 2016-09-12 HK HK16110776.1A patent/HK1222559A1/zh unknown
- 2016-12-01 HK HK16113676A patent/HK1225300A1/zh unknown
-
2019
- 2019-05-17 HR HRP20190920TT patent/HRP20190920T1/hr unknown
- 2019-07-03 CY CY20191100700T patent/CY1122033T1/el unknown
-
2020
- 2020-02-21 AU AU2020201277A patent/AU2020201277A1/en not_active Abandoned
- 2020-04-03 JP JP2020067766A patent/JP2020125304A/ja not_active Withdrawn
-
2021
- 2021-03-10 HR HRP20210406TT patent/HRP20210406T1/hr unknown
- 2021-03-24 CY CY20211100261T patent/CY1124399T1/el unknown
-
2022
- 2022-06-07 JP JP2022092222A patent/JP2022120010A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190920T1 (hr) | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| PH12015501404B1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| WO2014031769A3 (en) | Treatment of diseases associated with inflammation | |
| BR112015020918A2 (pt) | métodos para tratar o hcv | |
| WO2015099838A3 (en) | Compositions and methods of treating ocular diseases | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| BR112015024621A2 (pt) | c. novyi para o tratamento de tumores sólidos em seres humanos | |
| WO2016044839A3 (en) | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds | |
| MX2016006179A (es) | Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. | |
| WO2014075084A3 (en) | Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid | |
| BR112018000383A2 (pt) | métodos para tratar hcv | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| JP2014520874A5 (hr) | ||
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| CL2015002627A1 (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol | |
| MX2015011347A (es) | Tratamiento sistemico y topico combinado de tejidos con trastorno. | |
| BR112015019524A2 (pt) | tratamento de combinação | |
| WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| MA45378A (fr) | Compositions comprenant du timolol et leur utilisation dans le traitement de la rosacée par administration topique | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой |